A Research Guide for
ALS (Lou Gehrig’s Disease)

The standard ALS diagnostic workup includes:

• Clinical examination — a neurologist looks for a combination of upper motor neuron signs (spasticity, brisk reflexes, Babinski sign) and lower motor neuron signs (weakness, wasting, fasciculations) in multiple body regions.
• Electromyography (EMG) and nerve conduction studies — the most important diagnostic test. EMG detects lower motor neuron degeneration by recording electrical activity in muscles. It can show denervation in muscles that are not yet clinically weak, supporting the diagnosis.
• MRI of the brain and spinal cord — primarily to exclude structural problems (tumors, cervical myelopathy, syrinx) that can mimic ALS.
• Blood tests — to exclude metabolic, endocrine, and inflammatory causes: complete blood count, metabolic panel, thyroid function, vitamin B12, creatine kinase, paraneoplastic antibodies (in atypical cases), and others as clinically indicated.
• Lumbar puncture — not always required, but may be done to exclude inflammatory or infectious conditions.

The Gold Coast criteria (consensus 2019; published 2020) simplified the diagnostic framework for ALS. They require:

1. Progressive motor impairment documented by history or clinical examination.
2. Upper and lower motor neuron signs in at least one body region, OR lower motor neuron signs in at least two body regions.
3. Exclusion of other conditions that could explain the findings (by investigation, including EMG and imaging).

These replaced the older El Escorial and Awaji criteria, which were useful for research but sometimes delayed diagnosis by requiring spread to multiple body regions before the diagnosis could be confirmed. The Gold Coast criteria allow earlier, more confident diagnosis.

Several treatable conditions can look like ALS, which is why the diagnostic workup is thorough:

• Cervical myelopathy — spinal cord compression from disc disease or arthritis. Can cause upper and lower motor neuron signs in the arms and legs. Treated surgically.
• Multifocal motor neuropathy (MMN) — an immune-mediated condition causing progressive asymmetric weakness without sensory loss. Treatable with intravenous immunoglobulin (IVIG). Nerve conduction studies show conduction block.
• Myasthenia gravis — autoimmune disease affecting the neuromuscular junction. Can cause bulbar symptoms (speech, swallowing) and limb weakness. Treatable.
• Kennedy disease (spinal and bulbar muscular atrophy) — a genetic condition (X-linked, CAG repeat in the androgen receptor gene) that affects lower motor neurons in men. Progresses much more slowly than ALS.
• Inclusion body myositis (IBM) — an inflammatory muscle disease that can mimic ALS, especially in older adults with asymmetric weakness.

If there is any diagnostic uncertainty, a second opinion from a neuromuscular specialist or ALS center is appropriate and strongly encouraged.

ALS is a diagnosis with profound implications, and the average time from first symptom to diagnosis is roughly 12 months. A second opinion from a neurologist with ALS expertise is reasonable in any case and especially important if the presentation is atypical, the diagnostic workup was limited, or the patient and family want additional confidence. Most ALS centers welcome referrals for diagnostic confirmation.

• C9orf72 — the most common genetic cause of ALS, accounting for roughly 40% of familial and 7% of sporadic cases. It is a hexanucleotide repeat expansion. C9orf72 ALS is also frequently associated with frontotemporal dementia (FTD). Multiple therapies targeting C9orf72 are in clinical trials.
• SOD1 — the second most common cause, accounting for roughly 20% of familial and 2% of sporadic cases. SOD1 mutations are now clinically actionable because tofersen (Qalsody) is FDA-approved specifically for SOD1-ALS under accelerated approval (based on the VALOR trial showing reduction in plasma neurofilament light chain; confirmatory trials are ongoing to verify clinical benefit). This single fact makes SOD1 testing essential for every person diagnosed with ALS.
• TARDBP (TDP-43) — mutations in this gene account for a smaller proportion of cases. TDP-43 protein aggregation is a hallmark of most ALS, but TARDBP gene mutations are less common.
• FUS — associated with younger-onset ALS. Less common but important for genetic counseling.

Until recently, genetic testing was offered mainly to people with a family history. The approval of tofersen for SOD1-ALS changed the equation. The AAN and EAN now recommend that genetic testing (at minimum for SOD1 and C9orf72) be offered to all people with ALS, regardless of family history, because:

• SOD1 mutations have a targeted therapy (tofersen).
• C9orf72 expansion has therapies in clinical trials.
• Family history is unreliable — incomplete penetrance, early death of family members, or unknown paternity can hide a genetic cause.
• Results affect family members’ risk and reproductive planning.

Genetic counseling should accompany testing. The implications of a positive result extend to blood relatives, each of whom may have a 50% chance of carrying the mutation (for autosomal dominant genes). Presymptomatic testing of at-risk family members is available but is a deeply personal decision that should be made with professional genetic counseling.

Pregnancy with ALS is uncommon but does happen, and it can be navigated — but it is genuinely high-risk and needs a coordinated team planned well ahead of delivery: your neurologist, a high-risk pregnancy doctor (maternal-fetal medicine specialist), a breathing (respiratory) specialist, and an anesthesiologist. The central concern is breathing. ALS gradually weakens the muscles that power breathing, and in the last months of pregnancy a growing baby pushes up on the diaphragm and adds to the body's oxygen demands — so breathing needs to be monitored closely through the pregnancy, and non-invasive breathing support (BiPAP) may be needed sooner than it otherwise would be. Nutrition and the extra fatigue of pregnancy also need attention. Delivery should be planned in advance rather than improvised: the team will think through the safest approach for breathing, and there are important anesthesia considerations — certain muscle-relaxant drugs used in surgery must be avoided in ALS, and the choice between a spinal/epidural and general anesthesia depends on your breathing strength. None of this is meant to frighten, but to make clear that a pregnancy alongside ALS is a specialist, team-managed situation. If you are pregnant or considering it, raise it with your neurologist early so the right team can be assembled.

The ALS medicines have limited safety information in pregnancy and breastfeeding, so decisions are made carefully and individually with your team. Riluzole has little human pregnancy data and animal studies showed some effects at high doses, so it is generally avoided in pregnancy unless the benefit is judged to outweigh the risk, and breastfeeding on it is generally not advised. Edaravone and tofersen also have minimal pregnancy data, and decisions are individualized. Several medicines used for symptoms (for muscle stiffness, cramps, saliva, mood, sleep) also have pregnancy considerations and may need to be reviewed or changed. The practical points: if you are of childbearing age and starting an ALS medicine, discuss reliable contraception and your pregnancy plans up front; if you are planning a pregnancy, ask your team to review every medicine you take before you conceive so any changes can be made safely; and if you discover you are pregnant, do not stop or change medicines on your own — call your team promptly so the risks of each medicine can be weighed against the risks of stopping it.

If you carry a known ALS gene mutation (such as SOD1, C9orf72, FUS, or TARDBP), or ALS runs in your family, you may worry about passing it on. These genes are usually inherited in a "dominant" pattern, which means each child has about a 50% chance of inheriting the mutation — though, importantly, inheriting a mutation does not always mean a person will develop ALS (this is especially true for C9orf72, where some carriers never become ill, and the age it might appear is unpredictable). A genetic counselor is the key person to help you understand your specific situation, and there are several reproductive options to discuss, all valid and personal:

• Testing embryos before pregnancy (PGT-M with IVF): embryos created through IVF can be tested for the family mutation, and only unaffected embryos transferred. This is an established option for clearly disease-causing mutations and needs to be planned ahead of time.
• Testing during pregnancy: chorionic villus sampling (CVS) or amniocentesis can test the baby for a known family mutation.
• Other paths: using donor eggs or sperm, adoption, or choosing to conceive without testing — with full understanding of the odds.

For genes with uncertain penetrance like C9orf72, these decisions are especially complex, because a test result does not give a clear yes-or-no about future illness. There is no "right" choice — only the one that fits your values, ideally worked through with a genetic counselor and, where helpful, a fertility specialist. Because some of these options take time and are best arranged before a pregnancy, it is worth starting the conversation early. ALS itself does not directly reduce fertility, but advancing disease can limit options, which is another reason to plan ahead.

Riluzole was the first drug approved for ALS (1995) and remains the most widely used. It works by reducing glutamate-mediated excitotoxicity. Key facts:

• Extends median survival by roughly 2–3 months in clinical trials.
• The benefit may be larger in real-world use over longer periods, based on observational data.
• Dose: 50 mg twice daily, on an empty stomach.
• Side effects are generally mild: nausea, fatigue, elevated liver enzymes (liver function should be monitored).
• Most ALS specialists recommend starting riluzole at diagnosis.

The modest benefit shown in trials should not lead to nihilism. Riluzole is well-tolerated, inexpensive (generic), and provides a measurable, if small, survival advantage. It is the floor, not the ceiling, of treatment.

Tofersen is an antisense oligonucleotide (ASO) that targets SOD1 messenger RNA, reducing the production of the toxic SOD1 protein. It was approved by the FDA under accelerated approval in 2023 for ALS caused by SOD1 mutations. Key facts:

• Administered by intrathecal injection (lumbar puncture) — monthly after an initial loading phase.
• The VALOR trial showed significant reduction in SOD1 protein and neurofilament light chain (a marker of nerve damage) but did not meet its primary clinical endpoint over 28 weeks.
• Longer-term open-label data suggest clinical benefit, particularly when started earlier in the disease course.
• Only for patients with a confirmed SOD1 mutation — which is why SOD1 genetic testing is essential.
• Side effects include injection-site reactions, headache, and in rare cases, myelitis or papilledema.

Tofersen represents a new category: gene-targeted therapy for ALS. Even if its clinical benefit is still being defined, it validates the approach of targeting specific genetic causes, and similar therapies are in development for C9orf72 and other genetic forms.

Edaravone is a free radical scavenger approved for ALS in 2017 (intravenous) and 2022 (oral suspension). Its status is controversial:

• The pivotal Japanese trial showed a modest slowing of functional decline in a highly selected subgroup of early-stage patients.
• A larger, broader confirmatory trial did not show benefit.
• Some clinicians still prescribe it, particularly for patients who match the original trial population. Others have stopped using it.
• The oral formulation is more convenient than the original intravenous version.

International regulatory divergence: The EAN 2024 guideline does not recommend edaravone, citing insufficient evidence from the broader confirmatory trial. The FDA has not withdrawn approval. This means US and European clinical practice differ on this drug — US neurologists may still prescribe it; European MND specialists generally do not. In Japan, where edaravone was developed and first approved, it remains available.

Discuss with the ALS team whether edaravone is appropriate for the individual situation. The honest answer is that the evidence is mixed.

AMX0035 (sodium phenylbutyrate-taurursodiol, brand name Relyvrio) was approved under accelerated approval in 2022 based on a small trial. The larger confirmatory PHOENIX trial (NCT05021536) failed to show benefit. The manufacturer voluntarily withdrew the drug in April 2024. It is no longer available.

This outcome is a reminder that accelerated approvals require confirmatory evidence, and that the ALS community’s hope for new treatments must be balanced by rigorous evaluation of evidence.

The ALS research pipeline is more active than at any previous time. Areas of particular interest include:

• Gene-targeted therapies — antisense oligonucleotides for C9orf72 (multiple in trials), gene therapy approaches for SOD1 and other targets.
• The HEALEY Platform Trial — an adaptive platform trial testing multiple drug candidates simultaneously against a shared placebo arm. This design accelerates evaluation and reduces the number of patients who receive placebo.
• Anti-inflammatory and immune-modulating approaches — targeting neuroinflammation, which is increasingly recognized as a driver of progression.
• Stem cell therapies — some in legitimate clinical trials, but see the warning about unregulated clinics below.

ClinicalTrials.gov lists current ALS trials. The ALS Association and I AM ALS maintain searchable trial-matching tools.

Rozebalamin is an ultra-high-dose mecobalamin (methylcobalamin) 50 mg intramuscular injection, manufactured by Eisai. It was approved in Japan in September 2024 and is now commercially available there. This is not a vitamin supplement — it is a pharmacological-dose disease-modifying therapy administered at roughly 50–100 times the approved Methycobal (mecobalamin) dose — far above any over-the-counter supplement.

• The Phase 3 JETALS trial (130 patients with early-stage ALS, within one year of onset) showed a 43% slowing of ALSFRS-R decline compared to placebo (p=0.01; NCT03548311).
• JETALS did not measure survival. A ~500–600 day survival signal is sometimes cited for early-treated patients, but it comes from a post-hoc analysis of an earlier, separate trial (Study 761) — not JETALS — and is not confirmed (see below).
• The benefit was specific to early-stage disease — patients started later in their disease course did not show the same magnitude of benefit.
• Approved and launched commercially in Japan (September 24, 2024). Currently available only in Japan.
• Sources: Eisai press release, Current Opinion in Neurology 2024.

Masitinib is an oral tyrosine kinase inhibitor developed by AB Science (France) that targets neuroinflammation by inhibiting mast cells and microglia. It is not yet approved for ALS but has generated notable clinical trial data.

• A Phase 2b/3 randomized controlled trial showed a 27% slowing of ALSFRS-R decline at 48 weeks in normal progressors, 42% in the mild-to-moderate disease subgroup, and survival extended by more than 2 years in a subgroup analysis.
• The European Medicines Agency’s CHMP refused conditional marketing authorization in October 2024, citing insufficient overall evidence for approval at that time.
• A new confirmatory Phase 3 trial (AB23005, 408 patients) is now enrolling across Europe.
• Sources: NeurologyLive, ALS Association.

EMERGING — Discuss with your ALS team. Masitinib is not yet approved; access is currently through clinical trials only.

Ropinirole is a dopamine agonist normally used for Parkinson’s disease and restless legs syndrome. Researchers at Keio University in Japan have been investigating it as a repurposed therapy for ALS using a novel iPSC-guided (induced pluripotent stem cell) precision medicine approach.

• The Phase 1/2a ROPALS trial (20 patients) found ropinirole to be safe and tolerable in ALS patients. Participants maintained muscle strength during treatment, and an open-label extension showed 27.9 additional weeks of disease-progression-free survival compared to placebo.
• The innovative approach used patient-derived motor neurons grown from iPSCs to predict which patients might respond to the drug before enrolling them in the trial.
• Source: Cell Stem Cell 2023.

EMERGING — Very early-stage research with a small patient group. The iPSC-guided approach is scientifically interesting but requires larger confirmatory trials before clinical significance can be established. Discuss with your ALS team.

Nanocurcumin is a nano-formulated version of curcumin (the active compound in turmeric) designed to improve absorption. A small pilot study explored it as an add-on to riluzole in ALS.

• A pilot Phase 2 randomized, double-blind, placebo-controlled trial (54 patients, Iran, 12 months) tested nanocurcumin 80 mg/day added to standard riluzole.
• The primary finding was a lower rate of major events (death or need for mechanical ventilation): 3.7% in the nanocurcumin group versus 22.2% in the placebo group (p=0.036).
• ALSFRS-R decline did not differ significantly between groups.
• Source: PMC.

Knowing what has failed in rigorous testing is as important as knowing what has succeeded. Patients and families may encounter claims about these agents online; the evidence shows they do not help in ALS:

• Trehalose — tested in the HEALEY ALS Platform Trial. NEGATIVE — did not demonstrate benefit over placebo.
• Arimoclomol — tested in a Phase 3 trial. NEGATIVE — failed to meet its primary or secondary endpoints.
• Relyvrio (sodium phenylbutyrate-taurursodiol) — the Phase 3 PHOENIX confirmatory trial failed; the manufacturer voluntarily withdrew the drug in April 2024.
• Diaphragm pacing — a randomized trial showed it worsened survival compared to NIV alone. Not recommended.

These results are disappointing but important. They protect patients from wasting time and money on ineffective treatments and reinforce why rigorous clinical trials are necessary.

It helps to hold an honest, balanced view of where ALS medicines stand today — neither dismissing them nor expecting more than they can give. The truth is that the approved disease-modifying drugs slow the disease modestly; none stops or reverses it, and there is not yet a cure. Riluzole, the mainstay, adds a real but limited survival benefit and is worth taking by almost everyone, started early. Tofersen is genuinely exciting but applies only to the small group with a SOD1 mutation. Edaravone's benefit is debated and it suits a specific subgroup. That honest picture can feel deflating, but two things make it less so. First, the intervention with the largest proven benefit is not a drug at all but comprehensive care at a specialized ALS clinic — coordinated breathing, nutrition, mobility, communication, and symptom management, which together add more time and far more quality of life than any single medicine. Second, the research landscape is the most active it has ever been, with gene-targeted therapies and smarter trials moving quickly. The healthiest stance combines realism with genuine hope: take the proven treatments, lean hard on specialized multidisciplinary care, consider clinical trials, and measure success not only in time but in living as fully and comfortably as possible. Be cautious of any source — especially online — that promises a cure or a dramatic reversal; that is exactly where false hope and wasted money tend to live.

When evaluating any treatment claim for ALS, ask:

• Is the evidence from a peer-reviewed journal and a randomized controlled trial, or from testimonials and case reports?
• Has it been tested specifically in ALS patients?
• Are the results replicated — or is it a single small study?
• Does the person recommending it have a financial interest in selling it?
• Are ALS specialists at major academic centers using it?

Unregulated stem cell clinics, many operating outside the United States or in states with limited oversight, actively target people with ALS. These clinics typically charge tens of thousands of dollars per treatment, provide stem cell injections that have not been proven safe or effective in rigorous clinical trials, sometimes cause serious harm (infections, tumor formation, worsening neurological function), and offer no peer-reviewed evidence of benefit.

Legitimate stem cell research in ALS exists and is being conducted through proper clinical trials at academic medical centers. If interested in stem cell therapy, ask the ALS team about clinical trials — never go to an unregulated clinic.

Many supplements and alternative therapies are marketed for ALS. None has been proven to change the course of the disease in rigorous clinical trials. Some may be harmless; others can interfere with medications or have side effects. The responsible approach:

• Discuss any supplement with the ALS team before starting it.
• Be especially cautious of anything that claims to cure or reverse ALS.
• Do not replace proven interventions (riluzole, NIV, nutrition support) with unproven ones.
• If something truly worked, the ALS clinical community would know about it and be using it.

A multidisciplinary ALS clinic is a coordinated team of specialists who see the patient together, typically in a single visit every 2–3 months. The team usually includes:

• Neurologist (ALS specialist) — oversees diagnosis, medications, disease monitoring, and clinical trial access.
• Physical therapist — exercise programs, mobility assessment, equipment recommendations.
• Occupational therapist — adaptive equipment for daily activities, home modification, energy conservation.
• Speech-language pathologist — swallowing assessment, communication strategies, voice banking, augmentative and alternative communication (AAC) devices.
• Respiratory therapist or pulmonologist — breathing assessment (FVC, SNIP), non-invasive ventilation (NIV), cough assist devices.
• Dietitian — nutritional assessment, weight monitoring, caloric supplementation, feeding tube planning.
• Social worker — financial resources, disability applications, emotional support, community services, advance care planning.
• Palliative care specialist — symptom management, quality of life, goals-of-care conversations (not only at end of life).

This model works because ALS affects multiple body systems simultaneously, and coordinated care catches problems before they become crises.

ALS Association Certified Treatment Centers of Excellence and ALS Association Recognized Treatment Centers have met standards for multidisciplinary care. The ALS Association maintains a searchable directory at als.org. The Muscular Dystrophy Association (MDA) also operates ALS care centers.

For patients in the Mountain West, the University of Utah Motor Neuron Disease / ALS Clinic (801-805-7575) is a regional referral center with a full multidisciplinary team. If travel is a barrier, ask about telehealth options — many ALS clinics now offer hybrid in-person and telehealth visits.

ALS does not have a formal staging system like cancer. “Early stage” in this guide refers to the period when the person has noticeable weakness in one or two body regions but remains largely independent in daily activities, can still speak clearly (or with only mild difficulty), can still eat safely by mouth, and breathing function is near normal. This is the window of maximum opportunity. Nearly every time-sensitive preparation — voice banking, legal documents, equipment ordering, financial applications, clinical trial enrollment — is easier, faster, and more effective when done during this period.

• Establish care at a multidisciplinary ALS clinic. This is the first and most important step.
• Start riluzole. Begin disease-modifying medication promptly.
• Get genetic testing. At minimum for SOD1 and C9orf72. If SOD1-positive, discuss tofersen with the ALS team.
• Bank your voice. Do this now, while speech is clear. It cannot be done later.
• Complete legal and financial documents. Advance directive, healthcare power of attorney, durable power of attorney, will, and POLST/MOLST form. An elder law or disability attorney who understands ALS is valuable.
• Apply for Social Security Disability Insurance (SSDI). ALS is on the Compassionate Allowances list, meaning expedited processing — but the application still takes time.
• Apply for Medicare. ALS patients are exempt from the standard 24-month SSDI waiting period for Medicare — coverage begins 5 months after SSDI eligibility.
• Stay physically active. Moderate exercise is beneficial (see the exercise section below).
• Address mental health. Depression and anxiety are common and treatable. They are not signs of weakness. The ALS team can help.
• Explore clinical trials. The early stage is when the most trial options are available.

Voice banking involves recording a set of phrases (typically a few hours of recording) that software uses to create a synthetic voice that sounds like you. Several platforms are available:

• ModelTalker (modeltanker.com) — free, developed by Nemours Children’s Health. Records roughly 1,600 sentences. The resulting voice can be used on speech-generating devices.
• SpeakUnique (speakunique.co.uk) — creates a synthetic voice from recordings. Can sometimes work with already-weakened speech.
• Apple Personal Voice — built into iOS 17 and later. Records roughly 15 minutes of phrases on the device and creates a personal voice usable with Live Speech across Apple devices.
• Message banking — a complementary approach: recording common phrases, expressions, laughter, and emotional utterances in your own voice for playback. Team Gleason provides guidance.

The ALS clinic’s speech-language pathologist can guide the process and recommend the best option. The critical message: do not wait.

Voice banking can feel strange or upsetting to do early, when your speech is still strong — it asks you to prepare for a loss that has not happened yet. But the families who have done it almost universally describe it as worthwhile, and there are good reasons to act while you can. The practical one is simple and unforgiving: a synthetic voice is built from recordings of your current speech, so the window closes as speech weakens, and doing it early captures a fuller, more natural-sounding voice. The deeper reason is about identity and connection. Your voice is part of who you are, and being able to keep "speaking" in something that sounds like you — rather than a generic computer voice — matters enormously to many people and to those who love them. Beyond the formal voice banking, message banking lets you record specific phrases, your laugh, terms of endearment, jokes, and the everyday expressions that are uniquely yours, preserved in your real voice for the future. It is also worth holding onto a larger truth: losing the ability to speak is not losing the ability to communicate. Modern communication technology — from tablet apps to eye-gaze systems that let people compose words with eye movements alone — allows people with advanced ALS to keep conversing, working, writing, and connecting. Acting early on voice banking, and getting to know these tools before you need them, means that if speech does fade, your voice and your ability to be heard do not have to fade with it.

• Moderate-intensity exercise (not exhausting) maintains cardiovascular fitness, mood, and function without accelerating the disease.
• Range-of-motion and stretching exercises help manage spasticity and prevent contractures.
• Overwork weakness — exercise to the point of exhaustion — should be avoided. The guideline is: if a muscle is excessively fatigued or weak the next day, the intensity was too high.
• A physical therapist who understands ALS should design and periodically adjust the exercise program.
• Swimming and pool-based exercise can be excellent options because water supports body weight and reduces fall risk.

The goal is to stay as active as safely possible, not to build strength. Activity preserves what is there, supports mood, and maintains cardiovascular health.

• ☐ Confirmed diagnosis reviewed with neurologist; second opinion obtained if needed
• ☐ Multidisciplinary ALS clinic appointment scheduled or attended
• ☐ Riluzole started (discuss with ALS team)
• ☐ Genetic testing ordered (at minimum SOD1 and C9orf72)
• ☐ Voice banking started (do not delay)
• ☐ Records folder created: all medical records, test results, medication lists
• ☐ Advance directive and healthcare power of attorney drafted
• ☐ SSDI application filed (ALS qualifies for Compassionate Allowances)
• ☐ Medicare eligibility explored (no 24-month waiting period for ALS)
• ☐ Financial counselor or social worker contacted at ALS clinic
• ☐ Physical therapy assessment scheduled
• ☐ Clinical trial options reviewed (clinicaltrials.gov, ALS Association trial-matching)
• ☐ Family informed; support network identified

Decisions about work are deeply personal and depend on the type and pace of the disease. A few practical considerations:

• FMLA (Family and Medical Leave Act) — provides up to 12 weeks of job-protected leave for the patient and for family caregivers. Apply through the employer’s HR department.
• ADA (Americans with Disabilities Act) — requires employers to provide reasonable accommodations. Examples include voice-to-text software, modified schedules, ergonomic equipment, and remote work arrangements.
• Long-term disability insurance — if employer-provided or privately purchased, file a claim promptly. Review the policy’s definition of disability and waiting period.
• Health insurance continuity — if leaving employment, explore COBRA continuation, marketplace plans, Medicaid, and the accelerated Medicare pathway for ALS.
• Life insurance and financial planning — consult a financial advisor or elder law attorney. Some life insurance policies offer accelerated death benefits for terminal diagnoses.

The ALS clinic social worker is an invaluable resource for navigating these decisions.

• Ankle-foot orthoses (AFOs) — braces that support foot drop, one of the earliest mobility problems. A custom-fitted AFO from an orthotist improves walking safety.
• Canes and walkers — provide stability as balance and leg strength decline. A rollator (wheeled walker with seat) allows rest breaks.
• Power wheelchair — for many people with ALS, a power wheelchair is inevitable and should be ordered early. The evaluation, customization, insurance process, and delivery can take 3–6 months or longer. Waiting until the person cannot walk means weeks or months of unnecessarily restricted mobility and increased fall risk. Features to consider: tilt and recline for comfort and pressure relief, head support, elevating leg rests, and the ability to accommodate future communication devices.
• Stairlifts and ramps — home modifications should be evaluated early. An occupational therapist or ALS clinic social worker can guide the process.

Falls are a major source of injury in ALS. Practical steps:

• Remove loose rugs and clutter from walkways.
• Install grab bars in bathrooms and near bed.
• Use a shower chair or bench.
• Ensure adequate lighting, especially at night.
• Acknowledge when walking becomes unsafe and transition to a wheelchair — this is not giving up, it is staying safe.

An occupational therapist can assess the home for modifications. Common changes include widening doorways for wheelchair access, installing a ramp at the entrance, a hospital bed with adjustable head and foot sections, a Hoyer lift or ceiling-mounted track lift for transfers, a roll-in shower or walk-in tub, and environmental control systems (voice- or switch-activated) for lights, doors, and temperature. Many ALS organizations offer grants for home modifications.

• Stage 1: Speech is mostly clear — this is the time for voice banking, message banking, and establishing familiarity with communication technology.
• Stage 2: Speech is slurred but understandable — a voice amplifier can help. Speech strategies (slowing down, facing the listener, reducing background noise) extend functional communication.
• Stage 3: Speech is difficult to understand — a speech-generating device (SGD) becomes primary. Options include tablet-based apps and dedicated devices. Many use the banked voice.
• Stage 4: No functional speech, limited hand function — eye-gaze technology. A camera mounted on a screen tracks eye movement, allowing the user to select letters, words, and phrases by looking at them. This technology is remarkably effective and is used by many people with advanced ALS for years.

Technology can fail. Power outages happen. Devices break. Always have low-tech backup communication methods available:

• An alphabet board or letter board (partner scans rows/columns, patient signals with blink or sound).
• A predetermined set of yes/no signals (e.g., one blink for yes, two for no; or thumb up/down).
• An “emergency needs” card with the most critical messages pre-printed.

The speech-language pathologist at the ALS clinic coordinates the communication plan and can evaluate, recommend, and help fund devices through insurance and equipment loan programs.

Multiple studies have shown that weight loss in ALS is associated with worse outcomes. The reasons are interconnected: weakened muscles increase metabolic demand, swallowing difficulty reduces caloric intake, and malnutrition accelerates muscle loss. Maintaining or even slightly gaining weight is protective. The ALS clinic should monitor weight at every visit.

Dysphagia (swallowing difficulty) develops in most people with ALS, whether bulbar-onset or limb-onset. Signs include coughing or choking during meals, wet or gurgly voice quality after swallowing, food taking longer to chew and swallow, weight loss, and fear of eating. Strategies include:

• Texture modification — soft, moist foods are easier to swallow than dry or crumbly foods. A dietitian can guide specific modifications.
• Thickening liquids — thin liquids (water, juice) are often the most difficult to swallow safely. Thickening agents reduce aspiration risk.
• Smaller, more frequent meals with high caloric density.
• Positioning: sitting upright, chin tuck during swallowing.
• The speech-language pathologist performs formal swallowing assessments (clinical and/or instrumental) to guide safe swallowing strategies.

A gastrostomy tube (feeding tube placed directly into the stomach) is one of the most important decisions in ALS care. Key points:

• Timing is critical. The tube should be placed while breathing function is still adequate (typically FVC above 50%) because the procedure carries more risk when respiratory function is severely compromised. Waiting too long can mean the window for safe placement closes.
• It does not mean giving up eating. Many people with a feeding tube continue to eat favorite foods by mouth for pleasure while using the tube to ensure adequate nutrition and hydration.
• Types: PEG (percutaneous endoscopic gastrostomy, placed with endoscopy) and RIG (radiologically inserted gastrostomy, placed with imaging guidance — this may be safer in patients with compromised breathing because it avoids sedation).
• It extends survival. Studies consistently show that maintaining adequate nutrition through a feeding tube is associated with longer survival.

This is a decision to discuss with the ALS team well before it becomes urgent. Early, open conversation reduces crisis decision-making.

• High-calorie, high-protein foods — avocado, nut butters, full-fat dairy, olive oil, protein shakes, and smoothies can add calories in small volumes.
• Meal preparation — pre-preparing meals and freezing portions reduces the daily burden on the patient and caregiver.
• Hydration — thickened liquids if thin liquids cause choking; adequate fluid intake is essential for secretion management and overall health.
• Supplements — a multivitamin and vitamin D are reasonable. Beyond that, discuss with the dietitian rather than self-prescribing.
• Enjoyment — food is not only fuel. Preserving the social and pleasurable aspects of eating matters for quality of life, even when texture modification is needed.

Non-invasive ventilation — delivered through a mask over the nose or nose and mouth — is the most important intervention in ALS respiratory care. Key facts:

• NIV improves survival by an average of roughly 7–13 months in studies — far more than any drug.
• NIV improves quality of life by reducing breathlessness, improving sleep quality, reducing morning headaches, and reducing fatigue.
• It is typically started when symptoms of respiratory insufficiency appear (shortness of breath, orthopnea, morning headaches, daytime drowsiness) or when pulmonary function tests show decline (FVC below 50–80% of predicted, depending on the guideline).
• Earlier introduction and consistent use are associated with better outcomes. Many ALS clinics now introduce NIV earlier than traditional guidelines suggest.
• Adherence matters. Mask fitting, comfort adjustments, and respiratory therapist follow-up are essential to successful long-term use.

Watch for and report these symptoms to the ALS team:

• Shortness of breath, especially when lying flat (orthopnea)
• Morning headaches (from carbon dioxide retention overnight)
• Excessive daytime sleepiness or fatigue
• Difficulty sleeping, frequent awakenings
• A weak cough or inability to clear secretions
• Use of accessory muscles (neck, shoulder) to breathe
• A decline in voice volume or the ability to count aloud on a single breath

Pulmonary function tests (forced vital capacity, or FVC, and sometimes SNIP — sniff nasal inspiratory pressure) should be checked at every ALS clinic visit.

A mechanical insufflation-exsufflation device (cough assist machine, e.g., CoughAssist) helps clear secretions from the airways when the natural cough becomes weak. It works by delivering a deep breath through the mask (insufflation) followed by rapid negative pressure (exsufflation), simulating a strong cough. It is an important complement to NIV and should be available once cough strength begins to decline.

Diaphragm pacing (surgical implantation of electrodes to stimulate the diaphragm) was once investigated for ALS. A randomized trial showed that it actually worsened survival compared to NIV alone. It is not recommended for ALS and should not be pursued.

Tracheostomy with invasive ventilation is the decision to surgically create an airway in the neck and connect to a mechanical ventilator. This can sustain breathing indefinitely but is a major decision with profound implications:

• It requires 24/7 caregiver support and suctioning.
• The level of care required is substantial and affects the entire family.
• It does not stop ALS from progressing — the disease continues to affect other muscles.
• Some people on invasive ventilation live for many years and maintain meaningful quality of life, especially with good communication technology and a robust support system.
• Others choose not to pursue it, preferring comfort-focused care as breathing weakens.

There is no right answer. This is a deeply personal decision that should be made with the ALS team, palliative care, and the family well in advance of a respiratory crisis. A crisis is the worst time to make this decision.

Supplemental oxygen alone (without ventilation) can be harmful in ALS. The problem in ALS is not primarily a lack of oxygen — it is a failure to exhale carbon dioxide due to weak breathing muscles. Giving oxygen alone can suppress the drive to breathe, leading to dangerous carbon dioxide buildup. The correct intervention is ventilatory support (NIV), not supplemental oxygen alone. Oxygen may be used as a supplement to NIV in specific situations, but only under medical direction.

Non-invasive ventilation — usually a BiPAP machine — is one of the most important and life-extending tools in ALS, and it is far less frightening than it sounds. It is simply a small bedside machine that gently pushes air through a mask to help your weakened breathing muscles, most often used at night at first. People are often surprised by how much better they feel once they start: many of the symptoms that creep up unnoticed — morning headaches, daytime exhaustion, poor sleep, fuzzy thinking, breathlessness lying flat — are caused by under-breathing at night, and BiPAP frequently relieves them, restoring better sleep and more daytime energy. A few practical truths help. The first nights can take some getting used to, and the mask is the key to success — there are many styles (nasal, full-face, nasal "pillows"), and it is worth trying several with the respiratory team until one feels comfortable; a good fit makes all the difference. Starting early, before a breathing crisis, makes it much easier to adjust at your own pace. The benefit grows the more you use it — a few hours a night to start, often expanding over time — and using it well genuinely adds months of life and improves how you feel day to day. It does not mean things are suddenly dire; it means you are getting ahead of a problem rather than waiting for it. If the first try is uncomfortable, tell your team rather than giving up — adjustments to the mask, pressures, and humidification usually solve it.

Sialorrhea occurs because weakened swallowing muscles cannot manage normal saliva production. Treatments include:

• Anticholinergic medications: glycopyrrolate, atropine sublingual drops, hyoscyamine, amitriptyline.
• Botulinum toxin injections into the salivary glands (effective, lasts 3–4 months).
• Salivary gland radiation (low-dose) — for refractory cases.
• A portable suction device for managing pooled saliva.

While thin saliva may pool, mucous secretions can become thick and difficult to manage, especially with NIV use or dehydration. Strategies: adequate hydration, room humidification, guaifenesin (a mucolytic), N-acetylcysteine (mucolytic), nebulized saline, and a mechanical cough assist device.

Pseudobulbar affect causes episodes of involuntary, uncontrollable laughing or crying that may not match the person’s actual emotional state. It results from damage to upper motor neuron pathways controlling emotional expression. It is not a psychiatric condition and is not a sign of depression. Treatment: dextromethorphan-quinidine (Nuedexta) is FDA-approved specifically for PBA and is often highly effective. Understanding that PBA is a neurological symptom, not an emotional one, is important for both the patient and the family.

• Spasticity — muscle stiffness from upper motor neuron involvement. Treated with baclofen (oral or intrathecal pump for severe cases), tizanidine, stretching and range-of-motion exercises, and positioning.
• Cramps — painful involuntary muscle contractions. Common in ALS, especially early. Stretching, mexiletine (an antiarrhythmic that also treats cramps), quinine (less commonly used), and magnesium may help.

ALS is often described as a painless disease, and the motor neurons themselves may not generate pain. But people with ALS frequently experience pain from immobility (joint stiffness, pressure from sitting), muscle cramps, spasticity, and musculoskeletal strain. Pain is under-recognized and under-treated in ALS. The ALS team should ask about pain at every visit, and patients should report it. Treatments include physical therapy, repositioning, appropriate analgesics, and treatment of the underlying cause (cramps, spasticity).

Depression and anxiety are common in ALS and are significantly undertreated. They are not inevitable consequences of the diagnosis — they are medical conditions that respond to treatment. SSRIs (sertraline, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine), and counseling are effective. Mirtazapine can be particularly useful because it treats depression, anxiety, and insomnia while also stimulating appetite.

Sleep disturbance has multiple causes in ALS: respiratory insufficiency (the most important to identify), pain, cramps, immobility, depression, and anxiety. NIV often dramatically improves sleep quality when respiratory weakness is the cause.

Fatigue in ALS is often multifactorial: respiratory insufficiency, poor sleep, depression, deconditioning, and increased effort to perform weakened movements. Addressing the underlying causes (starting NIV, treating depression, optimizing nutrition, conserving energy with adaptive equipment) is more effective than any stimulant medication.

Up to 50% of people with ALS experience some cognitive or behavioral changes, ranging from mild executive dysfunction (difficulty with planning, multitasking, word-finding) to full frontotemporal dementia (FTD, roughly 10–15%). Changes may include apathy, disinhibition, loss of empathy, and compulsive behaviors. C9orf72 expansion ALS carries a higher risk. The ALS team should screen for these changes, as they affect decision-making capacity, caregiver burden, and care planning.

• Full dependence on a power wheelchair with tilt and recline.
• Communication through speech-generating devices, typically with eye-gaze control.
• Continuous or near-continuous non-invasive ventilation, or a decision about tracheostomy.
• Nutrition through a gastrostomy tube, possibly with continued oral intake for pleasure.
• 24-hour caregiver assistance for positioning, transfers, hygiene, and equipment management.

People in this stage continue to make decisions, maintain relationships, experience joy, and live with dignity. Communication technology makes this possible. The goal of the ALS team is to support quality of life at every stage.

Even when all limb and speech function is lost, communication remains possible through eye-gaze technology, brain-computer interfaces (in research settings), and partner-assisted scanning with eye blinks or small facial movements. The critical principle: the ability to communicate must be preserved and supported at every stage. Loss of communication is not an inevitable consequence of advanced ALS — it is a failure of preparation and technology deployment.

Advanced ALS involves profound physical dependence, but it does not diminish a person’s right to make decisions, to be treated with respect, and to participate in the life around them. Practical ways to support dignity:

• Always address the person directly, not through their caregiver, even when communication is slow.
• Provide time for communication — do not finish sentences or anticipate answers.
• Include the person in decisions about their own care, schedule, and daily routine.
• Maintain personal grooming and appearance according to the person’s preferences.
• Create opportunities for social engagement, visits, and activities that the person values.
• Recognize that the person inside has not changed, even though the body has.

As respiratory muscles weaken beyond what NIV can support, two paths emerge:

• Tracheostomy and invasive ventilation — sustains breathing indefinitely. Requires intensive caregiving, suctioning, and support infrastructure. Some people live many years on invasive ventilation. This path is most feasible with strong family or institutional support, adequate financial resources, and the patient’s clear, informed wish.
• Comfort-focused care — focusing on symptom relief, peace, and dignity as breathing naturally weakens. Hospice care provides expert management of breathlessness, anxiety, and other symptoms. Morphine and benzodiazepines are used effectively to relieve the sensation of air hunger without hastening death when used appropriately.

Both paths are valid. Neither is the “right” answer. What matters is that the decision is made in advance, with full information, and that it reflects the patient’s own values and wishes.

• Accept specific offers of help. When people say “let me know if you need anything,” give them a specific task: drive to an appointment, prepare a meal, sit with the patient for two hours. Vague offers go unfulfilled; specific requests get done.
• Use organizing tools. Sites like Lotsa Helping Hands, Meal Train, or CaringBridge coordinate volunteers for meals, rides, and visits.
• Get respite care. Regular time away from caregiving is not selfish — it is essential. The ALS Association, MDA, and local agencies provide or fund respite care. Hospice also provides respite.
• Tend your own health. Caregivers who neglect their own medical appointments, sleep, and nutrition become less effective and more vulnerable to illness. Schedule your own medical visits. Maintain at least minimal exercise. Protect your sleep.
• Seek emotional support. Caregiver support groups (ALS Association, MDA, local hospice) connect you with others who understand. Individual counseling is valuable and not a sign of failure. Many caregivers experience anticipatory grief, depression, and anxiety that respond to treatment.

• Learn safe transfer techniques from the physical therapist to protect your own back.
• Learn equipment operation: NIV, cough assist, feeding pump, communication devices. Have written instructions posted and emergency contacts visible.
• Keep a daily log of medications, NIV hours, food/fluid intake, and symptoms. This saves time at clinic visits and ensures continuity when multiple caregivers are involved.
• Have backup plans for equipment failure, power outages (battery backup for NIV is essential), and caregiver illness.

There is no shame in reaching a point where home caregiving alone is no longer sustainable. Signs that additional support is needed:

• The caregiver is sleeping fewer than five hours per night consistently.
• The caregiver’s own health is deteriorating (weight loss, new medical problems, worsening chronic conditions).
• The caregiver feels persistent anger, resentment, or emotional numbness.
• The patient’s care needs exceed what one or two people can safely provide.
• Safety incidents (falls, medication errors, skin breakdown) are increasing.

Options include hiring home health aides (often covered by Medicaid waiver programs), transitioning to a skilled nursing facility, or enrolling in hospice (which provides nursing visits, aide services, and equipment at home). The ALS clinic social worker can help evaluate options and coordinate transitions.

• Advance directive / living will — a legal document stating what medical treatments the person does and does not want if they cannot speak for themselves.
• Healthcare power of attorney (healthcare proxy) — designates a person to make medical decisions if the patient cannot. Choose someone who will honor the patient’s wishes even if they differ from their own.
• POLST / MOLST form — a medical order (signed by a physician) that translates advance directive wishes into immediately actionable instructions for emergency responders. Particularly important for decisions about CPR, intubation, and hospital transfer.
• Durable power of attorney — for financial and legal decisions.
• Will and estate planning — should be completed while the person can participate.

These documents should be completed early in the disease, reviewed periodically, and shared with the ALS team, the healthcare proxy, and family members.

Palliative care is specialized medical care focused on relief of symptoms, pain, and stress — at any stage of the disease, alongside active treatment. It is not the same as hospice. Early palliative care involvement in ALS improves quality of life, helps with complex symptom management, facilitates goals-of-care conversations, and supports both patient and family. Every ALS patient should have access to palliative care from early in the disease.

Hospice provides comfort-focused care when the prognosis is six months or less. In ALS, hospice services include expert management of breathing symptoms and air hunger, pain and symptom control, emotional and spiritual support for patient and family, respite care for caregivers, bereavement support for family after death, and medications and equipment related to the terminal diagnosis. Hospice can be provided at home, in a hospice facility, or in some cases in a nursing facility. Referral to hospice is appropriate when the patient’s goals shift from prolonging life to maximizing comfort. It does not mean giving up — it means changing the focus of care.

The most common fear in ALS is dying from suffocation. It is important to know that respiratory failure in ALS, when properly managed, is typically peaceful. As carbon dioxide rises, the person becomes drowsy and eventually sleeps. Medications (low-dose morphine and anxiolytics) are used to relieve the sensation of breathlessness and anxiety. Hospice teams are expert at this. Most people with ALS who die under hospice care die peacefully, without the distress that families fear.

Grief after losing someone to ALS is complicated by the prolonged anticipatory grief during the illness, the physical exhaustion of caregiving, and the abrupt loss of purpose after months or years of intensive caregiving. Hospice bereavement services (available for 13 months after death), grief counseling, and peer support groups are all valuable. The ALS Association and MDA offer bereavement resources specifically for ALS families.

The pace of ALS research has accelerated dramatically. In the last five years alone, tofersen proved that gene-targeted therapy works in ALS, platform trials have transformed how quickly drug candidates can be evaluated, neurofilament light chain has emerged as a reliable biomarker of disease activity, genetic understanding has deepened to the point where multiple gene targets are being pursued, and the regulatory pathway for ALS therapies has been streamlined. None of this guarantees a near-term cure. But the direction of travel is unmistakable, and each advance builds the foundation for the next.

The first kind of hope is hope for a cure or a major breakthrough. This hope is not empty: the ALS research pipeline is more active than at any time in history. Gene-targeted therapies, platform trials, and a deeper understanding of ALS biology are generating real candidates. Tofersen proved that targeting a specific genetic cause of ALS is possible. The same approach is being developed for other genetic forms. Whether this translates into broadly effective treatments in the near term is uncertain — but the direction is real.

The second kind of hope is hope for today — for meaningful life, for connection, for dignity, for the ability to make decisions and be heard. This hope is not dependent on a cure. It is achieved through excellent multidisciplinary care, communication technology, a committed support team, and the daily choice to live fully within the constraints the disease imposes. Many people with ALS describe their lives as meaningful even in advanced disease. This is not denial; it is evidence of human resilience and the power of good care.

Much of life with ALS is shaped not by the disease's pace but by the choices and adaptations made along the way, and many people find genuine meaning and even joy within it. A few orientations help. Keep doing what matters to you, adapting how rather than abandoning what — technology is remarkable here: eye-gaze and voice-controlled computers, communication devices, environmental controls, and powered mobility let people keep working, creating, connecting, and participating long after they could not have before. Plan ahead so you are not caught in a crisis — arranging breathing support, communication tools, equipment, and your wishes in advance is itself a way of protecting your autonomy and peace of mind, and frees energy for living rather than scrambling. Protect relationships and connection, which matter more than almost anything; let people help, stay socially engaged, and make room for the ordinary pleasures and meaningful moments that are still entirely available. Tend to your mental health — anxiety, low mood, and grief are common and treatable, and support (counseling, peer groups, and treatment when needed) is a strength, not a weakness. And give yourself permission to define a good life on your own terms, by comfort, connection, dignity, and being heard rather than by a checklist of abilities. None of this denies the seriousness of ALS; it reflects what people who live well with it consistently describe — that with excellent care, the right tools, and a committed support team, life can remain rich and worth living through every stage.

• ALS Association — the largest ALS organization. Provides care services, advocacy, research funding, support groups, and the treatment center certification program. als.org. 800-782-4747.
• Muscular Dystrophy Association (MDA) — operates ALS care centers, provides equipment assistance, and funds research. mda.org. 800-572-1717.
• I AM ALS — a patient-led movement focused on advocacy, community, clinical trial matching, and policy change. iamals.org.
• Team Gleason — provides assistive technology (communication devices, eye-gaze systems), home modifications, and adventure experiences for people with ALS. teamgleason.org.
• ALS Therapy Development Institute (ALS TDI) — a nonprofit biotechnology research lab dedicated to ALS drug development. also.als.net.
• Les Turner ALS Foundation — comprehensive care, research, and support. lesturnerals.org.

Connecting with others living with ALS is valuable for practical advice and emotional support. The ALS Association and MDA offer local in-person and virtual support groups for both patients and caregivers. Online communities (ALS Forums at alsforums.com, I AM ALS community, and various social media groups) provide 24/7 peer support. Many people find that peer connection — especially with others who truly understand ALS — is among the most helpful supports available.

• Answer ALS — a large-scale research initiative collecting biological data from ALS patients to accelerate drug discovery. answerals.org.
• Target ALS — funds collaborative ALS research and drug development. targetals.org.
• Project ALS — funds research into treatments and cures. projectals.org.
• ALS ONE — supports research, patient care, and families. alsone.org.
• Everything ALS — community platform for sharing experiences, treatment information, and clinical trial updates. everythingals.org.

Many of these organizations also provide patient assistance programs, equipment grants, and connections to specialized ALS resources.

ALS is on the Social Security Administration’s Compassionate Allowances list, meaning expedited processing of disability claims. Applications are typically approved within weeks rather than months. Apply as soon as possible after diagnosis. Contact: 800-772-1213, ssa.gov.

ALS is one of only a few conditions where the standard 24-month SSDI waiting period for Medicare is waived. Medicare coverage begins 5 months after SSDI eligibility is established (which is the 5-month SSDI waiting period). This means people with ALS can access Medicare much sooner than most disability recipients. Medicare covers physician visits, hospital care, durable medical equipment (wheelchairs, hospital beds, NIV, cough assist), and home health services. Contact: 800-633-4227, medicare.gov.

Veterans with ALS are eligible for service-connected disability benefits regardless of when or where they served. The VA presumes that ALS is service-connected for any veteran who served at least 90 days of continuous active duty. This provides disability compensation, medical care, equipment, and caregiver support. Contact the VA ALS registry: 877-222-8387.

• ALS Association equipment loan programs — provide wheelchairs, communication devices, hospital beds, and other equipment at no cost.
• MDA equipment assistance — helps with durable medical equipment not covered by insurance.
• Team Gleason — funds assistive technology (speech-generating devices, eye-gaze systems) and home modifications.
• State assistive technology programs — every state has an assistive technology program that provides equipment loans, demonstrations, and funding guidance. Find your state program at ataporg.org.
• Insurance appeals — if insurance denies equipment, appeal. The ALS clinic social worker can provide medical necessity letters. Many denials are reversed on appeal.

• How confident are you in the diagnosis? Are there any remaining tests to complete or mimics to exclude?
• What type of ALS do I have (limb-onset, bulbar-onset, respiratory-onset)?
• Can you refer me to a multidisciplinary ALS clinic?
• Should I start riluzole now?
• Will you order genetic testing, especially for SOD1 and C9orf72?
• Are there clinical trials I should consider?

• What is my current ALSFRS-R score, and how has it changed?
• What is my current FVC (breathing test), and does it indicate I should start NIV?
• Should I start the process for a feeding tube now, before my breathing declines?
• When should I begin voice banking?
• What equipment should I be ordering now to avoid gaps later?
• Are there new clinical trials available?

• Can you connect me with a social worker to help with SSDI, Medicare, and financial planning?
• What home modifications should I plan for?
• Can you provide a referral for palliative care?
• What support groups are available for me and my family?
• How can I get respite care for my caregiver?
• What should I do in an emergency (choking, breathing difficulty, fall)?

• At diagnosis (weeks 1–4): Confirm diagnosis; connect with ALS clinic; start riluzole; order genetic testing (SOD1, C9orf72); begin voice banking; complete advance directive and healthcare power of attorney; apply for SSDI; start records folder; explore clinical trials.
• Early stage (months 1–6): Establish regular ALS clinic visits; physical and occupational therapy programs; communication technology evaluation; home modification assessment; caregiver training begins; if SOD1-positive, discuss tofersen.
• Progressive stage: Start NIV when indicated (FVC decline, symptoms); order power wheelchair before it is urgently needed; place feeding tube while breathing is adequate; transition to speech-generating device or eye-gaze technology; install home modifications; expand caregiver support.
• Advanced stage: Continuous NIV or tracheostomy decision; 24-hour care support; communication technology maintained and adapted; hospice referral when goals shift to comfort; bereavement support for family.

• Sudden breathing difficulty or shortness of breath at rest — contact the ALS team immediately. If severe, call 911 and ensure any POLST form is available for emergency responders.
• Choking episode that does not resolve quickly — use cough assist if available; if the airway remains obstructed, call 911.
• Fall with injury — seek medical attention; notify the ALS team. This is also a trigger to reassess mobility equipment and fall prevention.
• Chest infection with fever — respiratory infections are particularly dangerous in ALS. Contact the ALS team the same day.
• Rapid or unexpected change in the pace of decline — notify the ALS team. Sudden acceleration may indicate a complication (infection, depression, nutritional decline) or may prompt reassessment of the care plan.
• FVC dropping below 50% — feeding tube should be placed soon if not already done; NIV should be initiated if not already in use.
• Significant weight loss — nutritional support should be intensified; feeding tube discussion should be moved up if not already done.

The major decision points in ALS follow a predictable sequence. While timing varies for each person, the decisions themselves are foreseeable and should be discussed in advance:

1. Diagnosis confirmed → Connect with ALS clinic → Start riluzole → Genetic testing → Voice banking → Legal documents → SSDI application.
2. Speech declining → Communication device evaluation → Speech-generating device or eye-gaze system.
3. Swallowing declining → Diet modification → Weight monitoring → Feeding tube discussion (place while FVC > 50%).
4. Breathing declining → FVC monitored → NIV initiated → Cough assist added → Tracheostomy or comfort care decision discussed.
5. Mobility declining → AFOs → Walker → Power wheelchair (order early) → Home modifications → Hoyer lift.
6. Advanced disease → 24-hour care plan → Hospice or continued aggressive care per patient’s wishes.

• What causes sporadic ALS — the 90% of cases with no identifiable genetic cause — remains unknown. Multiple hypotheses exist (environmental exposures, gene-environment interactions, stochastic cellular events), but none is proven.
• Why ALS is selective for motor neurons, while largely sparing sensory neurons, is not understood.
• Whether and how to treat presymptomatic carriers of ALS-causing mutations (identified through family testing) is an active research question. Tofersen is being studied in presymptomatic SOD1 carriers in the ATLAS trial (NCT04856982).
• The optimal timing for many interventions — when exactly to start NIV, when to place a feeding tube, when to introduce communication devices — varies by individual and is still guided more by clinical judgment than by definitive evidence.
• Whether exercise definitively slows progression or only maintains existing function is not fully settled, though the evidence supports moderate activity.
• How to effectively treat ALS that is not caused by an identifiable genetic mutation remains the central unsolved problem in the field.

It is not uncertain that multidisciplinary ALS clinic care extends survival and improves quality of life. It is not uncertain that non-invasive ventilation is the most effective survival intervention. It is not uncertain that maintaining nutrition matters, that voice banking must be done early, that genetic testing can identify actionable mutations, that tofersen benefits SOD1-ALS, that riluzole provides a modest survival advantage, that communication technology preserves autonomy and connection, or that proactive symptom management improves daily life. These facts are the foundation this guide rests on, and they are the reason for genuine, clear-eyed hope.

• AAC (augmentative and alternative communication) — any device, system, or method used to supplement or replace speech.
• AFO (ankle-foot orthosis) — a brace that supports the foot and ankle, commonly used for foot drop in ALS.
• ALSFRS-R — the ALS Functional Rating Scale-Revised, a 12-question tool used to track functional decline. Higher scores indicate better function.
• Antisense oligonucleotide (ASO) — a short synthetic strand of nucleic acid designed to bind to and reduce production of a specific protein. Tofersen is an ASO targeting SOD1.
• Aspiration — entry of food, liquid, or saliva into the airway. A major risk in ALS when swallowing is impaired.
• BiPAP — bilevel positive airway pressure; a form of non-invasive ventilation providing different pressures for inhaling and exhaling.
• Bulbar — relating to the brainstem region controlling speech, swallowing, and tongue movement.
• C9orf72 — the most common genetic cause of ALS; a repeat expansion in chromosome 9. Also associated with frontotemporal dementia.
• Cough assist (mechanical insufflation-exsufflation) — a device that simulates a strong cough to help clear airway secretions.
• Dysphagia — difficulty swallowing.
• Dysarthria — slurred or unclear speech caused by muscle weakness.
• EMG (electromyography) — a test recording electrical activity in muscles; the most important diagnostic test for ALS.
• Fasciculation — a visible involuntary muscle twitch caused by lower motor neuron irritability.
• FTD (frontotemporal dementia) — a form of dementia affecting personality, behavior, and language. Overlaps with ALS in some patients.
• FVC (forced vital capacity) — the maximum amount of air a person can exhale after a full breath. Used to track respiratory muscle strength in ALS.

• Gastrostomy — surgical placement of a feeding tube directly into the stomach (PEG or RIG procedure).
• Gold Coast criteria — simplified diagnostic criteria for ALS published in 2019, replacing the older El Escorial criteria.
• Intrathecal — administered into the spinal fluid via lumbar puncture. This is how tofersen is delivered.
• LMN (lower motor neuron) — nerve cell connecting the spinal cord to muscle. Its loss causes weakness, wasting, and fasciculations.
• Motor neuron — a nerve cell that controls voluntary muscle movement. ALS destroys both upper and lower motor neurons.
• NIV (non-invasive ventilation) — breathing support delivered through a mask, not a surgical airway. The most important survival-extending intervention in ALS.
• Orthopnea — shortness of breath when lying flat; an important early sign of diaphragm weakness in ALS.
• PBA (pseudobulbar affect) — involuntary episodes of laughing or crying not matching the person’s actual emotions. Treatable with dextromethorphan-quinidine.
• PEG (percutaneous endoscopic gastrostomy) — the most common method of placing a feeding tube, using an endoscope.
• POLST / MOLST — a medical order translating advance directive wishes into actionable instructions for emergency responders.

• Riluzole — the first FDA-approved drug for ALS. Reduces glutamate excitotoxicity and provides a modest survival benefit.
• RIG (radiologically inserted gastrostomy) — feeding tube placed using imaging guidance; may be safer than PEG for patients with reduced breathing capacity.
• Sialorrhea — excessive saliva or drooling, caused by inability to swallow saliva effectively.
• SNIP (sniff nasal inspiratory pressure) — a test of diaphragm strength; useful for tracking respiratory decline.
• SOD1 — superoxide dismutase 1 gene; mutations cause a form of ALS treatable with tofersen.
• Spasticity — abnormal muscle tightness and stiffness caused by upper motor neuron damage.
• Speech-generating device (SGD) — a device that produces spoken output from text or symbol input; critical communication tool in ALS.
• Tofersen (Qalsody) — an antisense oligonucleotide targeting SOD1 mRNA; the first gene-targeted therapy approved for ALS (FDA accelerated approval; confirmatory trials ongoing).
• Tracheostomy — surgical creation of an airway in the neck for long-term mechanical ventilation.
• UMN (upper motor neuron) — nerve cell connecting the brain to the spinal cord. Its loss causes spasticity, brisk reflexes, and Babinski sign.
• Voice banking — recording a person’s natural voice to create a synthetic version for use on communication devices.